Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multifactorial cardiovascular risk reduction in type 1 diabetes
2023-505794-32-04Phase 3Authorised
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 3
01
Overview
Phase 3 trial of semaglutide, finerenone and sotagliflozin in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Steno Diabetes Center Copenhagen. Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2023-505794-32-04.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505794-32-04.